uniQure's Stock Rises After Positive Phase I/II Results for AMT-130
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy QURE?
Source: Newsfilter
uniQure N.V. shares increased by 7.83% as the stock reached a 5-day high, reflecting a positive market reaction.
This rise comes amid recent news of positive results from uniQure's Phase I/II study of AMT-130 for Huntington’s disease, which demonstrated a 75% slowing of disease progression at high doses. Despite the positive trial results, the stock has faced significant challenges following the FDA's rejection of the Biologics License Application (BLA) for AMT-130, leading to heightened investor scrutiny and concerns about the company's future.
The implications of the recent trial results may provide some optimism for investors, but the ongoing regulatory hurdles and market sentiment will likely continue to influence the stock's performance in the near term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 27.660
Low
33.00
Averages
49.88
High
70.00
Current: 27.660
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
ClearPoint Neuro and UniQure Stocks Surge Following WSJ Report on Trump's Potential Plan to Dismiss FDA Commissioner Marty Makary
Company Overview: ClearPoint Neuro and Uniqure are involved in the biotechnology sector, focusing on innovative solutions in neurotechnology.
Market Reaction: Shares of ClearPoint Neuro have seen a significant increase following reports from the Wall Street Journal regarding potential changes in leadership at the FDA.
Leadership Changes: The reports suggest that former President Trump is considering firing FDA Commissioner Marty Makary, which has implications for regulatory processes in the biotech industry.
Investor Sentiment: The news has sparked interest among investors, leading to a spike in ClearPoint Neuro's stock prices as market participants react to the potential shifts in FDA oversight.
See More
uniQure Q1 2026 Earnings Call Insights
- Revenue Growth: uniQure reported revenue of $3.6 million for Q1 2026, a 125% increase from $1.6 million in the prior year, primarily driven by increased licensing revenue, indicating a strengthening market position and commercialization potential.
- R&D Expense Adjustment: Research and development expenses were $29.2 million, down from $36.1 million a year ago, mainly due to reduced external spending and personnel costs, providing greater financial flexibility for future clinical trials.
- Cash Flow Status: As of March 31, 2026, the company had $586.6 million in cash, cash equivalents, and investment securities, expected to fund operations into the second half of 2029, reflecting robust financial management.
- Clinical Trial Progress: uniQure is preparing to submit a marketing authorization application for AMT-130 in the U.K. and plans to hold a Type B FDA meeting in Q2 to discuss new clinical study designs, laying the groundwork for future product launches.
See More
uniQure Q1 Earnings Beat Expectations Despite Revenue Miss
- Earnings Highlights: uniQure reported a Q1 GAAP EPS of -$0.85, beating expectations by $0.01, indicating efforts in cost control, although overall financial performance still requires improvement.
- Revenue Growth: The company generated $3.56M in revenue, a 126.8% year-over-year increase, but fell short of expectations by $1.71M, reflecting market demand fluctuations and sales challenges.
- License Revenue Increase: The $2.0M increase in license revenue compared to the prior period suggests that the company's strategic focus on intellectual property is beginning to pay off, potentially laying the groundwork for future revenue growth.
- Market Reaction: Despite mixed financial indicators, uniQure's stock rose following regulatory updates, indicating market optimism regarding the prospects of its gene therapy asset AMT-130.
See More
uniQure Q1 Earnings Announcement Scheduled
- Earnings Release Date: uniQure is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of -$0.88, reflecting a 7.3% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The anticipated revenue for Q1 stands at $5.27 million, representing a substantial 235.7% year-over-year increase; however, the downward revisions in revenue estimates suggest a cautious market outlook on future growth.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen one upward revision and four downward adjustments, while revenue estimates have not been revised upward and have experienced six downward revisions, highlighting analysts' pessimistic expectations for the company's performance.
- Market Reaction: Despite facing financial hurdles, uniQure's stock has risen recently due to regulatory updates on its gene therapy, indicating a market optimism regarding the improved outlook for its AMT-130 asset.
See More
uniQure's Gene Therapy Receives Positive Regulatory Developments
- Stock Surge: uniQure (QURE) shares jumped approximately 22% on Thursday, reflecting market optimism regarding positive regulatory developments for its gene therapy candidate AMT-130, particularly amid uncertainty surrounding U.S. approval.
- Application Timeline: The company disclosed plans to submit a marketing authorization application for AMT-130 in the U.K. by Q3 2026, aiming to leverage constructive feedback from regulators to expedite the product's market entry.
- Regulatory Meeting Scheduled: Additionally, uniQure announced that the U.S. FDA has granted a Type B meeting, set for Q2 2026, to discuss the proposed Phase 3 trial decision for AMT-130 and to receive regulatory feedback on a data analysis plan for four-year results expected in Q3 2026.
- CEO's Positive Outlook: CEO Matt Kapusta expressed encouragement from the constructive feedback received from the MHRA, indicating the company's resilience and determination in navigating regulatory challenges as they work towards the submission for AMT-130.
See More
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
ClearPoint Neuro and UniQure Stocks Surge Following WSJ Report on Trump's Potential Plan to Dismiss FDA Commissioner Marty Makary
Company Overview: ClearPoint Neuro and Uniqure are involved in the biotechnology sector, focusing on innovative solutions in neurotechnology.
Market Reaction: Shares of ClearPoint Neuro have seen a significant increase following reports from the Wall Street Journal regarding potential changes in leadership at the FDA.
Leadership Changes: The reports suggest that former President Trump is considering firing FDA Commissioner Marty Makary, which has implications for regulatory processes in the biotech industry.
Investor Sentiment: The news has sparked interest among investors, leading to a spike in ClearPoint Neuro's stock prices as market participants react to the potential shifts in FDA oversight.
See More
uniQure Q1 2026 Earnings Call Insights
- Revenue Growth: uniQure reported revenue of $3.6 million for Q1 2026, a 125% increase from $1.6 million in the prior year, primarily driven by increased licensing revenue, indicating a strengthening market position and commercialization potential.
- R&D Expense Adjustment: Research and development expenses were $29.2 million, down from $36.1 million a year ago, mainly due to reduced external spending and personnel costs, providing greater financial flexibility for future clinical trials.
- Cash Flow Status: As of March 31, 2026, the company had $586.6 million in cash, cash equivalents, and investment securities, expected to fund operations into the second half of 2029, reflecting robust financial management.
- Clinical Trial Progress: uniQure is preparing to submit a marketing authorization application for AMT-130 in the U.K. and plans to hold a Type B FDA meeting in Q2 to discuss new clinical study designs, laying the groundwork for future product launches.
See More
uniQure Q1 Earnings Beat Expectations Despite Revenue Miss
- Earnings Highlights: uniQure reported a Q1 GAAP EPS of -$0.85, beating expectations by $0.01, indicating efforts in cost control, although overall financial performance still requires improvement.
- Revenue Growth: The company generated $3.56M in revenue, a 126.8% year-over-year increase, but fell short of expectations by $1.71M, reflecting market demand fluctuations and sales challenges.
- License Revenue Increase: The $2.0M increase in license revenue compared to the prior period suggests that the company's strategic focus on intellectual property is beginning to pay off, potentially laying the groundwork for future revenue growth.
- Market Reaction: Despite mixed financial indicators, uniQure's stock rose following regulatory updates, indicating market optimism regarding the prospects of its gene therapy asset AMT-130.
See More
uniQure Q1 Earnings Announcement Scheduled
- Earnings Release Date: uniQure is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of -$0.88, reflecting a 7.3% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations: The anticipated revenue for Q1 stands at $5.27 million, representing a substantial 235.7% year-over-year increase; however, the downward revisions in revenue estimates suggest a cautious market outlook on future growth.
- Estimate Revision Trends: Over the past three months, EPS estimates have seen one upward revision and four downward adjustments, while revenue estimates have not been revised upward and have experienced six downward revisions, highlighting analysts' pessimistic expectations for the company's performance.
- Market Reaction: Despite facing financial hurdles, uniQure's stock has risen recently due to regulatory updates on its gene therapy, indicating a market optimism regarding the improved outlook for its AMT-130 asset.
See More
uniQure's Gene Therapy Receives Positive Regulatory Developments
- Stock Surge: uniQure (QURE) shares jumped approximately 22% on Thursday, reflecting market optimism regarding positive regulatory developments for its gene therapy candidate AMT-130, particularly amid uncertainty surrounding U.S. approval.
- Application Timeline: The company disclosed plans to submit a marketing authorization application for AMT-130 in the U.K. by Q3 2026, aiming to leverage constructive feedback from regulators to expedite the product's market entry.
- Regulatory Meeting Scheduled: Additionally, uniQure announced that the U.S. FDA has granted a Type B meeting, set for Q2 2026, to discuss the proposed Phase 3 trial decision for AMT-130 and to receive regulatory feedback on a data analysis plan for four-year results expected in Q3 2026.
- CEO's Positive Outlook: CEO Matt Kapusta expressed encouragement from the constructive feedback received from the MHRA, indicating the company's resilience and determination in navigating regulatory challenges as they work towards the submission for AMT-130.
See More
